 Nov 1 2022
Recent article published in Molecular Oncology with MedRod® implants i...
|
 |
| PRICE QUOTE AND TECHNICAL INQUIRIES |
FOLLOW US
 |
|
|
LetrozoleFor mice and rats in metabolic studies, breast and prostate cancer xenograft, PDX and syngeneic studies and studies related to aromatase inhibitorsLetrozole (LTZ) implants for preclinical in vivo studies.
Drug release: At least 100 days, specific implants up to 6 months
Dose range: 5 µg – 75 µg/day
|  | |
|
